Annual Meeting of the Hematology Branch, CPAM | Professor Yajing Xu: Long-Term Follow-Up Management After Hematopoietic Stem Cell Transplantation—From Digital Solutions to Primary Care Collaboration

Annual Meeting of the Hematology Branch, CPAM | Professor Yajing Xu: Long-Term Follow-Up Management After Hematopoietic Stem Cell Transplantation—From Digital Solutions to Primary Care Collaboration

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Symposium, was held in Changsha. During the meeting, Professor Yajing Xu, Executive Chair and Director of Hematology at Xiangya Hospital, Central South University, was invited by Hematology Frontier to share her insights on the clinical challenges of long-term follow-up after hematopoietic stem cell transplantation (HSCT), standardized management models, and pathways for primary care collaboration. Her discussion aimed to promote the standardization of follow-up systems and improve long-term survival and quality of life for patients.
AACR China Voice | Qilu Pharmaceutical Showcases Multiple Innovative Breakthroughs at AACR, Driving Global Advances in Oncology Through Originative Innovation

AACR China Voice | Qilu Pharmaceutical Showcases Multiple Innovative Breakthroughs at AACR, Driving Global Advances in Oncology Through Originative Innovation

From April 17 to 22, 2026, the Annual Meeting of the American Association for Cancer Research—one of the most influential events in global oncology—was held. At this premier scientific forum, the R&D team of Qilu Pharmaceutical presented a series of independently developed innovative research achievements spanning cutting-edge fields such as antibody–drug conjugates (ADCs), bispecific and trispecific antibodies, and small-molecule therapies.
AACR China Voice | Professor Tao Zhu: First-in-Human Study of CLDN6 ADC QLS5132 Demonstrates Promising Efficacy and Safety, Opening New Directions for Platinum-Resistant Ovarian Cancer

AACR China Voice | Professor Tao Zhu: First-in-Human Study of CLDN6 ADC QLS5132 Demonstrates Promising Efficacy and Safety, Opening New Directions for Platinum-Resistant Ovarian Cancer

Platinum-resistant recurrent ovarian cancer (PROC) remains a major clinical challenge, characterized by poor overall prognosis, limited effective treatment options, high unmet medical need, and suboptimal safety profiles. Innovative treatment strategies are urgently needed.